Defender Capital LLC. Increases Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Defender Capital LLC. lifted its holdings in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 19.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,963,348 shares of the company’s stock after buying an additional 961,150 shares during the period. Lineage Cell Therapeutics comprises 1.1% of Defender Capital LLC.’s investment portfolio, making the stock its 12th biggest holding. Defender Capital LLC. owned approximately 2.71% of Lineage Cell Therapeutics worth $2,997,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Renaissance Technologies LLC boosted its holdings in Lineage Cell Therapeutics by 10.0% during the second quarter. Renaissance Technologies LLC now owns 583,622 shares of the company’s stock worth $582,000 after buying an additional 53,022 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter worth approximately $61,000. SG Americas Securities LLC acquired a new stake in shares of Lineage Cell Therapeutics in the 3rd quarter worth approximately $46,000. GSA Capital Partners LLP acquired a new position in Lineage Cell Therapeutics during the third quarter worth $84,000. Finally, MAI Capital Management raised its holdings in Lineage Cell Therapeutics by 2.2% during the third quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock worth $1,516,000 after purchasing an additional 35,907 shares during the last quarter. 62.47% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on LCTX shares. Maxim Group lowered their price target on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. D. Boral Capital reiterated a “buy” rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a report on Friday, January 3rd. Finally, HC Wainwright boosted their price target on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Lineage Cell Therapeutics has an average rating of “Buy” and a consensus price target of $4.80.

Lineage Cell Therapeutics Stock Performance

Shares of LCTX opened at $0.60 on Thursday. Lineage Cell Therapeutics, Inc. has a 12 month low of $0.48 and a 12 month high of $1.61. The stock has a market cap of $132.80 million, a price-to-earnings ratio of -5.02 and a beta of 1.18.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.